/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
Editor's note: The opportunity beckons. For the global pharmaceutical industry, it’s a race against the clock to vaccinate the world’s population against COVID-19. And, who better than India to supply the shots, in the cheapest and quickest way possible. The only Indian company that has made headlines so far is the Pune-based Serum Institute of India, which also happens to be the world’s largest manufacturer of vaccines. The company tied up with AstraZeneca, to bring a vaccine developed by the British-Swedish multinational firm along with UK’s Oxford University to the Indian market. SII will produce a billion doses of the vaccine by 2021-22, including 400 million this year, and is ready to push its stock into the market as soon as the vaccine is approved by the government. The other companies in the race have largely been silent so far. Two among them came into the limelight after Prime Minister Narendra Modi’s whistle-stop tour to take stock of vaccine production on 28 November. Along with SII’s Pune facility, he also visited the Zydus Cadila (Cadila Healthcare) unit in Ahmedabad and the Bharat …
Indian youngsters are experimenting with newer D2C brands like never before. Bewakoof’s early success and its 2022 acquisition by retail giant Aditya Birla Fashion should have given it the edge, but the company has been left behind.
The earnings of India’s oil refiners and other Nifty 50 companies have taken a hit. But IPO premiums suggest that investors seem unfazed.
The global health body has declared the latest outbreak a public health emergency of international concern as the rising cases are linked to more virulent strain of the virus.
